Recent progress in elucidating mechanisms underlying muscular dystrophy and muscle disease has dramatically increased the number of potentially druggable targets available for therapeutic intervention. Concurrently, hew approaches have increased the number of compounds that can be tested for activity against these targets. Together, these trends have stimulated the adoption of high-throughput screening (HTS) as a primary tool for early-stage drug discovery. HTS has already been applied to a limited set of muscular dystrophy targets, leading to therapeutics currently being tested in the clinic. This has increased enthusiasm worldwide and among CDMD Investigators for designing and implementing muscular dystrophy relevant HTS assays for drug discovery and elucidation of basic aspects of muscle cell biology. UCLA has already made a tremendous commitment to HTS screening on campus through the Molecular Shared Screening Resource (MSSR) to facilitate translational medicine, in general. Core B extends this set of resources to facilitate the screening of muscle/dystrophy relevant targets by providing manpower, cell models, expertise, eqiuipment and space for cell reprogramming, expansion and banking to support muscle centric projects. A major focus of the core is developing and distributing human patient cell based dystrophy models, including iDRM.(induced directly reprogrammable myotubes) and IPSC (induced pleurepotent stem cells), from patients with Duchenne and other dystrophies for use in HTS and validation of target hits and other interventions. Thus, the core maximizes impact by leveraging the existing UCLA investment in HTS technology by providing the needed resources and skills to "fill the gaps" to make muscle/dystrophy relevant assays readily and simply feasible on campus for center members.
Aim 1) To advise and assist users in muscle centric HTS assay development, application and data analysis in collaboration with the MSSR;
Aim 2) To develop, validate expand, bank and distibute primary/reprogrammed cells derived from Duchenne and other dystrophy patients;
Aim 3) To provide support, expertise, equipment and BSL2+ cuture space for utilization of developed cell based models for drug/therapy/target validation.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAR1-XZ (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Los Angeles
United States
Zip Code
DiFranco, Marino; Kramerova, Irina; Vergara, Julio L et al. (2016) Attenuated Ca(2+) release in a mouse model of limb girdle muscular dystrophy 2A. Skelet Muscle 6:11
Reyhan, Meral L; Wang, Zhe; Kim, Hyun J et al. (2016) Effect of free-breathing on left ventricular rotational mechanics in healthy subjects and patients with duchenne muscular dystrophy. Magn Reson Med :
Capote, Joana; Kramerova, Irina; Martinez, Leonel et al. (2016) Osteopontin ablation ameliorates muscular dystrophy by shifting macrophages to a pro-regenerative phenotype. J Cell Biol 213:275-88
Srinivasan, Subashini; Kroeker, Randall M; Gabriel, Simon et al. (2016) Free-breathing variable flip angle balanced SSFP cardiac cine imaging with reduced SAR at 3T. Magn Reson Med 76:1210-6
Brown, Robert; Lee, Hane; Eskin, Ascia et al. (2016) Leveraging ancestry to improve causal variant identification in exome sequencing for monogenic disorders. Eur J Hum Genet 24:113-9
Young, Courtney S; Hicks, Michael R; Ermolova, Natalia V et al. (2016) A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells. Cell Stem Cell 18:533-40
Kramerova, Irina; Ermolova, Natalia; Eskin, Ascia et al. (2016) Failure to up-regulate transcription of genes necessary for muscle adaptation underlies limb girdle muscular dystrophy 2A (calpainopathy). Hum Mol Genet 25:2194-2207
Gibbs, Elizabeth M; Marshall, Jamie L; Ma, Eva et al. (2016) High levels of sarcospan are well tolerated and act as a sarcolemmal stabilizer to address skeletal muscle and pulmonary dysfunction in DMD. Hum Mol Genet :
Mokhonova, Ekaterina I; Avliyakulov, Nuraly K; Kramerova, Irina et al. (2015) The E3 ubiquitin ligase TRIM32 regulates myoblast proliferation by controlling turnover of NDRG2. Hum Mol Genet 24:2873-83
Arboleda, Valerie A; Lee, Hane; Dorrani, Naghmeh et al. (2015) De novo nonsense mutations in KAT6A, a lysine acetyl-transferase gene, cause a syndrome including microcephaly and global developmental delay. Am J Hum Genet 96:498-506

Showing the most recent 10 out of 48 publications